Clinical Trial Update: Cetuximab and Lenalidomide in Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial update of cetuximab plus lenalidomide in head and neck squamous cell carcinoma. The study completed enrollment and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Chicago | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-11-24